Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
135
resultados
Última actualización
23/08/2025 [07:07:00]
Resumen de: EP4603477A1
The invention relates to an inhibitor targeting the coronavirus accessory protein ORF9b of formula I, or a pharmaceutical salt thereof, wherein the meanings for the various substituents are as disclosed in the description. Furthermore, the invention relates to its use as a medicament, particularly for the treatment of the hyperinflammation induced by highly pathogenic coronaviruses such as SARS-CoV-2, SARS-CoV or MERS.
Resumen de: MX2025004342A
The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.
Resumen de: WO2025171130A1
The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: WO2025170898A1
The present disclosure relates to compounds that act as inhibitors against the attachment of the SARS-CoV-2 virus, pharmaceutical formulations thereof, and methods of using the compounds to prevent and treat diseases associated with the SARS-CoV-2 virus.
Resumen de: WO2025169929A1
The present invention provides a method for treating a sequela of an infection by a SARS-CoV-2 virus, the method including administering an inhibitor of an RNA-dependent RNA polymerase (RdRp) of the virus to a patient who needs the treatment. Also provided are: a method for screening for a therapeutic agent for a sequela of an infection by the virus; and a model mouse useful for the method.
Resumen de: US2025257100A1
Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-CoV-2 or at risk of being exposed to SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.
Resumen de: KR20250122834A
본 발명은 코로나 독감 동시 진단 티슈에 관한 것으로, 합성 수지에 의하여 진단 수지가 검사자 피부와 접촉하지 않게 함으로써 현재의 바이러스 검사 방법은 시간이 오래 걸림 코로나와 독감을 동시 진단하지 못함 비 침습적인 방법이 부족하며, 효율적인 비용 관리도 어려움 문제점을 해소하도록 한 것이다. 즉, 본 발명은, 독감 진단 키트, 코로나 진단 키트에 있어서 진단 수지가 검사자 피부와 접촉하지 않게 코로나, 독감 수지 앞에 있고 사각형 모양으로 형성한 합성 수지, 코로나 균 접촉 시 색이 변할 수 있게 합성수지 사이에 있고 사각형 모양 형성한 코로나 진단 수지, 독감 균 접촉 시 색이 변할 수 있게 합성수지 사이에 있고 사각형 모양 형성한 독감 진단 수지로 포함하는 것을 특징으로 한다. 따라서, 본 발명은 합성 수지에 의하여 진단 수지가 검사자 피부와 접촉하지 않게 하여, 현재의 바이러스 검사 방법은 시간이 오래 걸림 코로나와 독감을 동시 진단하지 못함 비 침습적인 방법이 부족하며, 효율적인 비용 관리도 어려움 문제점을 해소하도록 함으로써, 기존의 현재의 바이러스 검사 방법은 시간이 오래 걸림 코로나와 독감을 동시 진단하지 못함 비 침습적인 방법이 부족하며, 효율적인 비용 관리도 어려움 문제�
Resumen de: US2025255842A1
The present invention concerns a treatment of Long COVID-19 by using specialized pro-resolving lipid mediators (SPM) or their active precursors. optionally in combination with a non-steroidal anti-inflammatory drug.
Resumen de: US2025255954A1
Disclosed herein is a new method referred to as Conformational Shifting by Distance and Volume Analysis (CS-DVA) which can be employed to change the dynamics of multi-state glycoproteins for altered immune responses. Also disclosed are stabilized spike antigens and methods of use thereof for SARS-COV-2 vaccines.
Resumen de: US2025258173A1
The present invention provides a method of immunologically detecting SARS-CoV-2, the method comprising detecting a SARS-CoV-2 N protein in a specimen taken from a subject by using the following antibodies (1) and (2):(1) a first antibody to a first epitope in a 306th to 339th amino acid region in the SARS-CoV-2 N protein, and(2) a second antibody to a second epitope in a 365th to 419th amino acid region in the SARS-CoV-2 N protein.
Resumen de: WO2025170972A1
The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: WO2025168689A1
The disclosure relates to treating and preventing coronavirus infections, in particular SARS-CoV-2. The disclosure also relates to treating or preventing cardiovascular symptoms associated with coronavirus infections, including blood clotting, heart attack, stroke, pulmonary embolism and/or thrombosis. The disclosure further relates to antibodies which may be used in such methods.
Resumen de: US2025257099A1
Described are lipopeptides that inhibit coronavirus fusion to a host cell. Thus a therapeutic for treating or preventing the common cold is described along with methods of inhibiting and/or treating an alphacoronavirus infection. The lipopeptides comprise a peptide unit comprising an amino acid sequence having a high degree of sequence identity to a sequence from the C-terminal heptad repeat of a betacoronavirus S protein, such as that of SARS-CoV-2.
Resumen de: MX2025003937A
The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.
Resumen de: WO2024074849A1
Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; PLL comprises a SARS-CoV-2 papain-like protease ligand, X comprises a divalent exit vector; X1 comprises a divalent exit vector; a and b are independently selected from 1 or 2; L comprises a divalent linker, and UL comprises an E3 ubiquitin ligase ligand. Also disclosed are pharmaceutical compositions comprising such compounds or combinations, and methods and reagents using the compounds. Compounds may have therapeutic uses and uses in research.
Resumen de: WO2024074848A1
Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; MPL comprises a SARS-CoV-2 main protease ligand, X comprises a divalent exit vector; Xi comprises a divalent exit vector; a and b are independently selected from 1 or 2; L comprises a divalent linker, and UL comprises an E3 ubiquitin ligase ligand. Also disclosed are pharmaceutical compositions comprising such compounds or combinations, and methods and reagents using the compounds. Compounds may have therapeutic uses and uses in research.
Resumen de: GB2638106A
A diagnostic device for detecting a first member of a reporter-analyte pair comprising: an inlet for receiving a liquid, biological sample; a porous membrane element comprising a detection portion, the detection portion being in liquid communication with the inlet, wherein the detection portion comprises a second member of the reporter-analyte pair and a variant of the second member of the reporter-analyte pair immobilisable thereon, and wherein an interaction between the first member of the reporter-analyte pair and the second member of the reporter-analyte pair is separately detectable from an interaction between the first member of the reporter-analyte pair and the variant of the second member of the reporter-analyte pair. Preferably the second members of the pair are immobilised at discrete sites and the device further comprises a control. Optionally the second membrane is a biological antigen such as a protein or polypeptide and the first member an antibody. Optionally the antigen is a COVID-19 S1 spike protein.
Resumen de: WO2024074651A1
This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical compositions comprising these compounds and the manufacture and use of these compounds and compositions in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The compounds and compositions may be useful in preventing death or complications arising due to chronic underlying conditions or comorbidities in patients infected with SARS- CoV-2 and related viruses.
Resumen de: KR102844027B1
본 발명은 N 유전자의 돌연변이를 포함하는 증식불능 SARS-CoV-2 백신주 및 이의 용도에 관한 것으로, 보다 자세하게는 SARS-CoV-2의 N (nucleocapsid) 유전자에 5개의 종결코돈(stop codon)을 삽입하여 N 유전자를 trans-complementation하지 않은 세포에서는 증식이 불가능한 SARS-CoV-2 백신주 및 이의 용도에 관한 것이다.
Resumen de: AU2023412579A1
An application of shenling baizhu in the preparation of a drug for treating psychoneurological symptoms of recovered COVID-19 patients.
Resumen de: US2025249088A1
Provided herein is an immunogenic composition comprising a synthetic antigen to COVID spike proteins, particularly the chimeric intermediate structure C-A Complex. Also disclosed herein is a method of preventing and/or treating a COVID infection in a subject in need thereof, by administering the immunogenic composition to the subject.
Resumen de: US2025248965A1
Compounds for use against a viral infection The invention relates to hexahydronaphthalen-2-one derivatives, such as petasol, petasin and isopetasol, for use in the prevention or the treatment of viral infections. In particular compounds extracted from Darksidea spp. are provided for use in the treatment of SARS-CoV-2 infection.
Resumen de: US2025250647A1
Coronavirus genomes comprising non-native SARS-CoV-2 RNAs having genetically inactivated spike (S), envelope (E), and membrane (M) genes, and optionally a genetically inactivated nucleocapsid (NP) gene, are provided. Such coronavirus genomes further include a reporter gene and a marker gene, and substitutions within a non-structural protein 1 (Nsp1) gene (such as K164A and H165A). Also provided are cells containing the coronavirus genomes, for example, stable cell clones having the isolated non-native coronavirus genome autonomously replicating inside the cells. Also provided are methods of using such cells, for example, methods of identifying anti-viral compounds, such as quantitative high-throughput screening methods that can optionally be performed in a biosafety level 2 (BSL2) laboratory.
Resumen de: US2025250312A1
A bifunctional peptide is provided, the bifunctional peptide comprising a virus binding moiety and a mucin binding moiety covalently bound to the virus binding moiety. The virus binding moiety is chosen from peptides binding to SARS-CoV-2, to influenza A, to influenza B, to rhinoviruses and other enteroviruses, to human parainfluenza virus, and/or to metapneuvirus. The mucin binding moiety is chosen from lectins such as trefoil factor 3.
Nº publicación: US2025250254A1 07/08/2025
Solicitante:
HINOVA PHARMACEUTICALS INC [CN]
HINOVA PHARMACEUTICALS INC
Resumen de: US2025250254A1
A compound represented by formula (I) or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof are provided. In formula (I), R1-R17 are each independently selected from hydrogen and deuterium, R18 and R19 are hydrogen, and R1-R19 are not simultaneously hydrogen. The deuterated compound and the salt, hydrate or solvate thereof have excellent metabolic stability and pharmacokinetic properties, and can be used in the manufacture of tubulin inhibitors, anti-cancer drugs, antiviral drugs, and drugs for the treatment of novel coronavirus pneumonia.
BOPI
Sede Electrónica
